References
- Cancer Genome Atlas Research, N., et al., Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med, 2016. 374(2): p. 135–45.
- Shuch B., et al., Current treatment Landscape of Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, Vol 35, No26, (Sept 10), 2017: pp 2981–2983
- Schmid, T.A. and M.E. Gore, Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol, 2016. 8(6): p. 348–371.
- Fukui, S., et al, Reversible Posteior Leukoencephalopathy Syndrome Developing After restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Case Reports in Medicine, Vol 2016, Article ID 6852951
- Stenman, M., et al, Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. Acta Oncologica, 58:3,306–312, DOI: 10.1080/0284186X.2018.1537505
- Khan, K.H. et al, Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori, 2012. 98: e139–e142.
- Hinduja, A., Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol, 2020. 11: p. 71.
- Gao, B., et al., Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry, 2018. 89(1): p. 14–20.
- Kastrup, O., et al., Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol, 2012. 259(7): p. 1383–9.
- Fugate, J.E. and A.A. Rabinstein, Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol, 2015. 14(9): p. 914–925.